{"entity":{"id":"shr-a1904","kind":"drug","name":"SHR-A1904","aka":[],"tldr":"SHR-A1904 is Hengrui's experimental antibody-drug conjugate aimed at Claudin 18.2, in a phase 3 trial against standard second-line treatment for advanced stomach cancer. Merck KGaA holds an option to license it outside China.","summary":"SHR-A1904 is a Claudin 18.2-directed antibody-drug conjugate from Jiangsu Hengrui. In October 2023 Merck KGaA, Darmstadt, announced a collaboration with Hengrui that licensed the PARP1 inhibitor HRS-1167 and included an option to an exclusive worldwide (ex-China) licence for SHR-A1904; whether the option has been exercised was not found in the sources read. Hengrui's phase 3 trial (NCT06649292) compares SHR-A1904 with the investigator's choice of paclitaxel, docetaxel or irinotecan, measuring overall survival, in second-line Claudin 18.2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma. Earlier and parallel trials test it in advanced solid tumours and pancreatic cancer, in combination with adebrelimab and chemotherapy, and in biliary tract, colorectal and neuroendocrine cancers. No results are recorded here.","status":"phase-3","asOf":"2026-11-03","links":[{"label":"Merck KGaA and Hengrui collaboration announcement, October 2023 (BioSpace copy)","url":"https://www.biospace.com/merck-kgaa-darmstadt-germany-strengthens-oncology-pipeline-through-strategic-partnership-with-hengrui-for-next-generation-selective-parp1-inhibitor-and-antibody-drug-conjugate"},{"label":"ClinicalTrials.gov: SHR-A1904 phase 3 in gastric cancer (NCT06649292)","url":"https://clinicaltrials.gov/study/NCT06649292"},{"label":"ClinicalTrials.gov: trials of SHR-A1904","url":"https://clinicaltrials.gov/search?intr=SHR-A1904"}],"tags":["pipeline","deal-asset"],"related":[],"cancers":["gastric","pancreatic","cholangiocarcinoma","colorectal"],"sections":[],"technologies":["adc"],"targets":["cldn18-2"],"drugs":[],"companies":["hengrui","merck-kgaa"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05277168","nct07450976","nct07102901","nct07110571","nct06547736","nct07700719"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit (ClinicalTrials.gov v2 + company press releases)","editedOn":"2026-11-03"},"modality":"Antibody-drug conjugate (Claudin 18.2)","mechanism":"An antibody that recognises Claudin 18.2, a protein exposed on many stomach, oesophageal-junction and pancreatic cancers, carries a drug payload into those cells. The payload is not named in the sources read.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/shr-a1904/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"},{"id":"merck-kgaa","kind":"company","name":"Merck KGaA (EMD Serono)","route":"/companies/merck-kgaa/"}],"trial":[{"id":"nct07450976","kind":"trial","name":"A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer","route":"/trials/nct07450976/"},{"id":"nct07110571","kind":"trial","name":"A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer","route":"/trials/nct07110571/"},{"id":"nct05277168","kind":"trial","name":"A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS","route":"/trials/nct05277168/"},{"id":"nct06547736","kind":"trial","name":"Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer","route":"/trials/nct06547736/"},{"id":"nct07102901","kind":"trial","name":"Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma","route":"/trials/nct07102901/"},{"id":"nct07700719","kind":"trial","name":"SHR-A1904 in Advanced Colorectal Cancer: an Exploratory Study","route":"/trials/nct07700719/"}]}}